Approved for use through 07/31/2008, OMR 0651-000 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE sation unless it contains a valid OMB control number

Application Number 10574316 Filing Date 2006-03-31 INFORMATION DISCLOSURE First Named Inventor Jong-Heon Kim STATEMENT BY APPLICANT

Under the Peperwork Reduction Act of 1995, no person

	for submission under 37 CFR 1.99)	Art Unit		I	
(1101101	To submission under 57 Cr R 1.55)	Examiner Name	Not	Yet Assigned	
		Attorney Docket Nu	mber	7093-006	
		U.S.PATEN	TS		
-		0.0.1 7.12.1			
1					

Pages, Columns, Lines where Name of Patentee or Applicant Examiner Cite Kind Patent Number Issue Date Relevant Passages or Relevant Initial\* Nο Code of cited Document Figures Appear 1

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATION

U.S.PATENT APPLICATION PUBLICATIONS										
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1									

If you wish to add additional U.S. Published Application citation information please click the Add button.

# FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	тя
	1	10-2003-69321	KR	A	2003-08-27	Kim		×
	2	10-2003-41735	KR	A	2003-05-27	Kim		×

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number		10574316 2006-03-31		
	Filing Date				
	First Named Inventor	Jong-	Heon Kim		
	Art Unit	Art Unit			
	Examiner Name	Not Y	ot Yet Assigned		
	Attorney Docket Numb	ber	7093-006		

Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, celaido, etc), date, pages(§), volume-issue number(s), publisher, city and/or country where publisher.	Ţ5	
	1			1

If you wish to add additional non-patent literature document citation information please click the Add button

# EXAMINER SIGNATURE

Examiner Signature	Date Considered	
*EXAMINER: Initial if reference considered, whether or n		
citation if not in conformance and not considered. Includ-	e copy of this form with next communication	to applicant.

1 See Kind Codes of USPTO Patent Documents at year, LISPTO.GOU, or MPEP 601.64. \* Enter office that issued the document, by the shoeting to code (WPLO STATE of Appended STATE). As a Continuent, by the shoeting of the Emporer must provate the serial number of the Patender and provide the serial number of the Patender document, "A Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language principation is attached.

#### 

#### CERTIFICATION STATEMENT

Please see	37	CFR	1.97	and	1.98	to	make	the	appropriate	select	ion(	\$
------------	----	-----	------	-----	------	----	------	-----	-------------	--------	------	----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.37[e/17].

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the conflication after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c).

See attached certification statement.

Hosoon Lee

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

### X None

Name/Print

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.35, 10.16. Please see CFR 1.4(d) for the form of the signature.

Registration Number

56737

Tom or the signature.			
Signature	/Hosoon Lee/	Date (YYYY-MM-DD)	2006-05-24

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to the fared by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 122 and 37 CFR.

1.14. This collection is estimated to take if hour to complicite, including gathering, preparing and submitting the completed application from the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petient and Tradenien's Office, in Superiment of Comments of Chief (A), Researchie, V.S. 2313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 22313-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-79) requires that you be given certain information in connection with your submission of the actuached form related to a patient application or patient. Accordingly, pursuant to the requirement of the Act, places be advised that: (1) the general authority for the collection of this information is \$5 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademank Office to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested private the private in the private patient of the patient

The Information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, megistrate, or administrative tribunal, including disclosures to opposing course in the course of settlement negotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552/a/mì.
  - A record releted to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designer, during an inspection of records concluded by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under subhority of 44 U.S.C. 2904 and 2908. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall be made in accordance value of the disclosure shall be made in accordance value.
- A record from this system of records may be disclosed, as a routine use, to the public effer either publication of the adjoination pursuant to 35 U.S.C. 122(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application, no prot public inspections or an issuant patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.